Show simple item record

dc.contributor.authorde Souza, NM
dc.contributor.authorAchten, E
dc.contributor.authorAlberich-Bayarri, A
dc.contributor.authorBamberg, F
dc.contributor.authorBoellaard, R
dc.contributor.authorClement, O
dc.contributor.authorFournier, L
dc.contributor.authorGallagher, F
dc.contributor.authorGolay, X
dc.contributor.authorHeussel, CP
dc.contributor.authorJackson, EF
dc.contributor.authorManniesing, R
dc.contributor.authorMayerhofer, ME
dc.contributor.authorNeri, E
dc.contributor.authorO'Connor, James, P, B
dc.contributor.authorOguz, KK
dc.contributor.authorPersson, A
dc.contributor.authorSmits, M
dc.contributor.authorvan Beek, EJR
dc.contributor.authorZech, CJ
dc.date.accessioned2019-10-07T15:16:45Z
dc.date.available2019-10-07T15:16:45Z
dc.date.issuedqen
dc.identifier.citationdeSouza NM, Achten E, Alberich-Bayarri A, Bamberg F, Boellaard R, Clement O, et al. Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Imaging. 2019 Aug 29;10(1):87.en
dc.identifier.pmid31468205en
dc.identifier.doi10.1186/s13244-019-0764-0en
dc.identifier.urihttp://hdl.handle.net/10541/622220
dc.description.abstractObserver-driven pattern recognition is the standard for interpretation of medical images. To achieve global parity in interpretation, semi-quantitative scoring systems have been developed based on observer assessments; these are widely used in scoring coronary artery disease, the arthritides and neurological conditions and for indicating the likelihood of malignancy. However, in an era of machine learning and artificial intelligence, it is increasingly desirable that we extract quantitative biomarkers from medical images that inform on disease detection, characterisation, monitoring and assessment of response to treatment. Quantitation has the potential to provide objective decision-support tools in the management pathway of patients. Despite this, the quantitative potential of imaging remains under-exploited because of variability of the measurement, lack of harmonised systems for data acquisition and analysis, and crucially, a paucity of evidence on how such quantitation potentially affects clinical decision-making and patient outcome. This article reviews the current evidence for the use of semi-quantitative and quantitative biomarkers in clinical settings at various stages of the disease pathway including diagnosis, staging and prognosis, as well as predicting and detecting treatment response. It critically appraises current practice and sets out recommendations for using imaging objectively to drive patient management decisions.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1186/s13244-019-0764-0en
dc.titleValidated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Imaging Centre, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surreyen
dc.identifier.journalInsights in Imagingen
dc.description.noteen]
refterms.dateFOA2019-10-27T19:33:35Z


Files in this item

Thumbnail
Name:
13244_2019_Article_764.pdf
Size:
1.092Mb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record